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To the Editor: O’Neill1 revealed the fact that the calcium–-
phosphorus product (Ca P) is an independent risk factor
for mortality and morbidity is also questionable in his review.
Although the Kidney Disease Outcomes Quality Initiative
(KDOQI) guideline states that the Ca P should be
maintained below 55 mg2 per 100 ml2,2 considering the
Ca P as well as serum Ca and P make the algorithms in
the KDOQI guideline complicated. As O’Neill indicated, in
the largest cross-sectional study, both serum Ca and serum P
were strongly associated with coronary calcification but
Ca P was not analyzed.3 We examined the relationship of
Ca P and serum Ca or serum P in 1395 patients with
hemodialysis. We did not find any correlation between
Ca P and serum Ca. Conversely, we found strong signi-
ficant correlation between Ca P and serum P (R¼ 0.95,
Po0.001, Figure 1). Because the serum Ca serum P can
usually be kept in an appropriate level by maintaining
serum P and corrected serum Ca within the target range,
Japanese guidelines for the treatment of secondary hyper-
parathyroidism in patients on dialysis did not adopt Ca P
for an index. Accordingly, Japanese guidelines consist of nine
blocks that depend on serum Ca levels and serum P levels
(high, suitable, low; 3 3) and indicate recommended
treatments in each block (Figure 2). Without adopting
Ca P for an index make guidelines simple, resulting in high
feasibility. We should reconsider the value of Ca P in
guidelines for Chronic kidney disease-Mineral and Bone
Disorder (CKD-MBD).
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Figure 1 | The relationship of CaP and serum P levels in HP
patients.
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Figure 2 | The management of serum P and Ca levels (Japanese guidelines for the treatment of secondary hyperparathyroidism in
patients on dialysis).
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